

# Financial Results for FY2016 & Outlook for FY2017

May 16, 2017



**(Cautionary Statement)**

Statements made in this material with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

## 1. Consolidated Financial Results for FY2016 Ended March 31, 2017

Financial Summary	4
Net Sales by Business Segments	5
Operating Income by Business Segments	6
Segment Analysis	7
Extraordinary Gains / Losses	12
Breakdown of Extraordinary Gains / Losses	13
Consolidated Balance Sheets	14
Consolidated Statements of Cash Flows	15
Segment Topics	16

## 2. Outlook for FY2017

Financial Summary	18
Net Sales by Business Segments	19
Operating Income by Business Segments	20
Segment Analysis	21
Consolidated Statements of Cash Flows	26

## (Reference: Segment Information)

Net Sales by Business Segments (Quarterly)	28
Operating Income by Business Segments (Quarterly)	30
Cost Elements etc.	32
Capital Expenditures by Business Segments	33
Estimated Capital Expenditures by Business Segments	34
Depreciation and Amortization by Business Segments	35
Estimated Depreciation and Amortization by Business Segments	36
Research & Development Expenses by Business Segments	37
Estimated Research & Development Expenses by Business Segments	38
Major Group Companies	39
Overseas Sales	40
Sales / Profits Transition	41
Interest-bearing Liabilities / D/E Ratio Transition	42
Cash Dividends / Payout Ratio Transition	43

# 1. Consolidated Financial Results for FY2016 Ended March 31, 2017


Unit; billions of yen

	FY2015	FY2016	Difference	Ratio
Net sales	2,101.8	<b>1,954.3</b>	<b>-147.5</b>	<b>-7.0%</b>
Operating income	164.4	<b>134.3</b>	<b>-30.1</b>	<b>-18.3%</b>
(Equity in earnings of affiliates)	(20.2)	<b>(41.2)</b>	(21.0)	-
(Net exchange gain / loss)	<b>(-8.5)</b>	<b>(-1.1)</b>	(7.4)	-
Ordinary income	171.2	<b>166.6</b>	<b>-4.6</b>	<b>-2.7%</b>
(Extraordinary gain / loss)	<b>(-13.6)</b>	<b>(-21.4)</b>	<b>(-7.8)</b>	-
(Income taxes)	<b>(-45.2)</b>	<b>(-28.1)</b>	(17.0)	-
Net income	112.4	<b>117.1</b>	4.7	-
(Net income attributable to non-controlling interests)	<b>(-30.9)</b>	<b>(-31.6)</b>	<b>(-0.6)</b>	-
Net income attributable to owners of the parent	81.5	<b>85.5</b>	4.0	4.9%
ROE	10.5%	<b>10.8%</b>		
Exchange rate (yen/USD)	120.15	<b>108.34</b>		
Naphtha price (yen/KL)	42,800	<b>34,700</b>		
Overseas sales ratio	61.3%	<b>60.7%</b>		

Unit; billions of yen

	FY2015	FY2016	Difference	Ratio	Sales Price Variance	Shipping Volume Variance	Foreign Currency Conversion Variance
Petrochemicals & Plastics	657.1	572.0	-85.1	-12.9%	-42.0	-9.3	-33.8
Energy & Functional Materials	209.0	205.9	-3.1	-1.5%	-13.0	13.7	-3.8
IT-related Chemicals	384.5	358.4	-26.1	-6.8%	-31.0	43.5	-38.6
Health & Crop Sciences	359.0	319.3	-39.7	-11.1%	-26.0	8.8	-22.5
Pharmaceuticals	435.5	444.2	8.7	2.0%	-7.0	40.3	-24.6
Others & Adjustments	56.6	54.4	-2.2	-3.9%	0.0	-2.2	-0.0
<b>Total</b>	<b>2,101.8</b>	<b>1,954.3</b>	<b>-147.5</b>	<b>-7.0%</b>	<b>-119.0</b>	<b>94.8</b>	<b>-123.3</b>


## Analysis




Unit; billions of yen

	FY2015	FY2016	Difference	Price Variance	Cost Variance	Shipping Volume Variance and Other	Total
Petrochemicals & Plastics	28.8	26.6	-2.2	9.0	-4.0	-7.2	-2.2
Energy & Functional Materials	2.8	7.2	4.4	0.5	0.0	3.9	4.4
IT-related Chemicals	19.9	10.3	-9.5	-35.0	17.5	8.0	-9.5
Health & Crop Sciences	77.5	46.2	-31.4	-18.5	-8.5	-4.4	-31.4
Pharmaceuticals	42.7	55.1	12.4	-7.0	-18.5	37.9	12.4
Others & Adjustments	-7.2	-11.0	-3.8	0.0	0.5	-4.3	-3.8
<b>Total</b>	<b>164.4</b>	<b>134.3</b>	<b>-30.1</b>	<b>-51.0</b>	<b>-13.0</b>	<b>33.9</b>	<b>-30.1</b>

## Analysis



## Sales



## Total ¥572.0 billion (-85.1 from FY2015)

### Sales price

-42.0

- Decline in market price of synthetic resins

### Volume


-9.3

- Less shipping volume due to restructuring of petrochemical business

### Foreign exchange

-33.8

## Operating income



## Total ¥26.6 billion (-2.2 from FY2015)

### Price variance

+9.0

- Better profit margin on MMA and raw materials for synthetic fibers

### Cost variance

-4.0

- Increase in cost of actuarial gain and loss


### Volume variance etc.

-7.2

- Temporary licensing revenue in FY2015
- Negative impact of stronger yen



## Sales



**Total ¥205.9 billion (-3.1 from FY2015)**

**Sales price**

**-13.0**

- Decline in selling price and stronger yen

**Volume**


**+13.7**

- Increase in shipment of resorcinol
- Increase in shipment of engineering plastics

**Foreign exchange**

**-3.8**

## Operating income



**Total ¥7.2 billion (+4.4 from FY2015)**

**Price variance**

**+0.5**

**Cost variance**


**0**

**Volume variance etc.**

**+3.9**

- Increase in shipment of resorcinol
- Increase in shipment of engineering plastics

## Sales



**Total ¥358.4 billion (-26.1 from FY2015)**

**Sales price**

**-31.0**

- Decline in selling price of polarizing film
- Decline in selling price of touchscreen panels

**Volume**


**+43.5**

- Increase in shipment of touchscreen panels
- Increase in shipment of polarizing film

**Foreign exchange**

**-38.6**

## Operating income



**Total ¥10.3 billion (-9.5 from FY2015)**

**Price variance**

**-35.0**

- Decline in selling price of polarizing film
- Decline in selling price of touchscreen panels

**Cost variance**

**+17.5**


- Rationalization of the use of raw materials

**Volume variance etc.**

**+8.0**

- Increase in shipment of touchscreen panels
- Increase in shipment of polarizing film

## Sales



**Total ¥319.3 billion (-39.7 from FY2015 )**

**Sales price**  
-26.0


- Lower market price for feed additive methionine

**Volume**  
+8.8

- New consolidation of Indian subsidiary

**Foreign exchange**  
-22.5

## Operating income



**Total ¥46.2 billion (-31.4 from FY2015 )**

**Price variance**  
-18.5

- Lower market price for feed additive methionine


**Cost variance**  
-8.5

- Increase in R&D cost
- Increase in cost of actuarial gain and loss

**Volume variance etc.**  
-4.4

- Negative impact of stronger yen

## Sales



**Total ¥444.2 billion (+8.7 from FY2015)**

**Sales price**

**-7.0**

- NHI price revision in Japan

**Volume**


**+40.3**

- Increase in shipment of Latuda® in North America

**Foreign exchange**

**-24.6**

## Operating income



**Total ¥55.1 billion (+12.4 from FY2015)**

**Price variance**

**-7.0**

- NHI price revision in Japan

**Cost variance**

**-18.5**

- Increase in sales expense

**Volume variance etc.**

**+37.9**

- Increase in shipment of Latuda® in North America

Unit; billions of yen

	FY2015	FY2016	Difference
Impairment loss	-24.7	-34.3	-9.6
Restructuring charges	-4.8	-18.9	-14.1
Gain on sale of investment securities	15.8	27.3	11.5
Gain on step acquisitions	-	3.4	3.4
Gain on sale of property, plant and equipment	-	1.0	1.0
Extraordinary gains / losses	-13.6	-21.4	-7.8

Gain on sales of investment securities

27.3 billion yen

Sales of investment securities held by Sumitomo Chemical  
and Sumitomo Dainippon Pharma

Impairment loss

34.3 billion yen

Major Items	Amount
Optical functional film production facilities	10.2 billion yen
High-purity alumina production facilities High-purity aluminum production facilities	6.7 billion yen
S-SBR production facilities	5.1 billion yen
Electrolyzers	3.4 billion yen
Nitric acid · Aniline production facilities	2.9 billion yen

Unit: billions of yen

	31-Mar-16	31-Mar-17	Difference
Current assets	1,187.9	<b>1,231.1</b>	43.2
Cash and cash equivalents	215.6	<b>193.3</b>	<b>-22.3</b>
Trade notes and accounts receivable	414.8	<b>455.2</b>	40.4
Inventories	402.3	<b>409.4</b>	7.1
Others	155.3	<b>173.2</b>	18.0
Non-current assets	1,474.2	<b>1,630.9</b>	156.7
Property, plant and equipment	642.2	<b>626.2</b>	<b>-16.0</b>
Intangible assets	187.3	<b>357.6</b>	170.3
Investment and other assets	644.8	<b>647.1</b>	2.3
<b>Total</b>	<b>2,662.2</b>	<b>2,862.1</b>	<b>199.9</b>

	31-Mar-16	31-Mar-17	Difference
Liabilities	1,571.4	<b>1,699.5</b>	128.2
Trade notes and accounts payable	205.2	<b>243.5</b>	38.4
Interest-bearing Liabilities	831.5	<b>875.3</b>	43.7
Others	534.7	<b>580.7</b>	46.1
Net assets	1,090.8	<b>1,162.5</b>	71.8
Shareholders' equity	643.7	<b>707.0</b>	63.3
Accumulated other comprehensive income	123.2	<b>113.3</b>	<b>-9.8</b>
Non-controlling interests	323.9	<b>342.2</b>	18.3
<b>Total</b>	<b>2,662.2</b>	<b>2,862.1</b>	<b>199.9</b>
Shareholders' equity ratio	28.8%	<b>28.7%</b>	<b>-0.1%</b>
D/E ratio	0.8	<b>0.8</b>	0.0

Unit: billions of yen

	FY2015	FY2016	Difference
Cash flows from operating activities	261.2	<b>187.4</b>	<b>-73.7</b>
Cash flows from investing activities	<b>-53.7</b>	<b>-199.7</b>	<b>-146.1</b>
Free cash flows	207.5	<b>-12.3</b>	<b>-219.8</b>
Cash flows from financing activities	<b>-178.0</b>	<b>-8.1</b>	169.8
Effect of exchange rate changes on cash and cash equivalents	<b>-14.3</b>	<b>-1.9</b>	12.4
Net change in cash and cash equivalents	15.3	<b>-22.3</b>	<b>-37.6</b>
Cash and cash equivalents at end of year	215.6	<b>193.3</b>	<b>-22.3</b>



<b>Petrochemicals &amp; Plastics</b>	<ul style="list-style-type: none"><li>● Integrated polyolefin film business</li><li>● Expanded polypropylene compound business globally</li><li>● Made polycarbonate joint venture a wholly owned subsidiary</li></ul>
<b>Energy &amp; Functional Materials</b>	<ul style="list-style-type: none"><li>● Decided to expand polyethersulfone production capacity</li><li>● Acquired majority stake in manufacturer of cathode materials for secondary batteries</li><li>● Decided to expand production capacity for lithium-ion secondary battery separators</li></ul>
<b>IT-related Chemicals</b>	<ul style="list-style-type: none"><li>● Expanded production capacity for glass-based touchscreen panels</li><li>● Decided to expand production capacity for film-based touchscreen panels</li><li>● Decided to expand color resist business globally</li></ul>
<b>Health &amp; Crop Sciences</b>	<ul style="list-style-type: none"><li>● Decided to strengthen research and development capabilities in Japan and North America</li><li>● Decided to expand methionine production capacity</li><li>● Acquired Indian agrochemicals company</li></ul>
<b>Pharmaceuticals</b>	<ul style="list-style-type: none"><li>● Offering early retirement program (Sumitomo Dainippon Pharma)</li><li>● Acquired Cynapsus Therapeutics Inc. developing treatment for Parkinson's disease</li><li>● Acquired Tolero Pharmaceuticals, Inc. developing treatment for hematologic malignancies</li></ul>

## 2. Outlook for FY2017


Unit; billions of yen

	FY2016	FY2017 (estimated)	Difference	Ratio
Net sales	1,954.3	<b>2,190.0</b>	235.7	12.1%
Operating income	134.3	<b>165.0</b>	30.7	22.8%
(Equity in earnings of affiliates)	(41.2)	<b>(35.0)</b>	<b>(-6.2)</b>	-
Ordinary income	166.6	<b>185.0</b>	18.4	11.0%
Net income attributable to owners of the parent	85.5	<b>100.0</b>	14.5	17.0%
ROE	10.8%	<b>11.8%</b>		
Exchange rate (yen/USD)	108.34	<b>110.00</b>		
Naphtha price (yen/KL)	34,700	<b>37,000</b>		

Unit; billions of yen

	FY2016	FY2017 (estimated)	Difference	Ratio	Sales Price Variance	Shipping Volume Variance	Foreign Currency Conversion Variance
Petrochemicals & Plastics	572.0	640.0	68.0	11.9%	-4.5	67.7	4.8
Energy & Functional Materials	205.9	250.0	44.1	21.4%	-1.5	44.8	0.8
IT-related Chemicals	358.4	385.0	26.6	7.4%	-28.5	48.3	6.8
Health & Crop Sciences	319.3	380.0	60.7	19.0%	2.0	54.4	4.3
Pharmaceuticals	444.2	480.0	35.8	8.1%	0.0	31.8	4.0
Others & Adjustments	54.4	55.0	0.6	1.0%	0.0	0.6	0.0
<b>Total</b>	<b>1,954.3</b>	<b>2,190.0</b>	<b>235.7</b>	<b>12.1%</b>	<b>-32.5</b>	<b>247.5</b>	<b>20.7</b>


## Analysis




Unit; billions of yen

	FY2016	FY2017 (estimated)	Difference	Price Variance	Cost Variance	Shipping Volume Variance and Other	Total
Petrochemicals & Plastics	26.6	27.0	0.4	-3.0	0.5	2.9	0.4
Energy & Functional Materials	7.2	12.0	4.8	-1.5	-1.5	7.8	4.8
IT-related Chemicals	10.3	21.0	10.7	-27.5	14.5	23.7	10.7
Health & Crop Sciences	46.2	60.0	13.8	1.0	-4.0	16.8	13.8
Pharmaceuticals	55.1	57.0	1.9	0.0	-18.0	19.9	1.9
Others & Adjustments	-11.0	-12.0	-1.0	0.0	0.0	-1.0	-1.0
<b>Total</b>	<b>134.3</b>	<b>165.0</b>	<b>30.7</b>	<b>-31.0</b>	<b>-8.5</b>	<b>70.2</b>	<b>30.7</b>

## Analysis



## Sales



**Total ¥640.0 billion (+68.0 from FY2016)**

**Sales price**

**-4.5**

- Decline in market price of synthetic resins

**Volume**


**+67.7**

- Commencement of sales of Rabigh Phase II products
- Consolidation of Sumika Polycarbonate as subsidiary

**Foreign exchange**

**+4.8**

## Operating income



**Total ¥27.0 billion (+0.4 from FY2016 )**

**Price variance**

**-3.0**

- Decline in market price of synthetic resins

**Cost variance**


**+0.5**

**Volume variance etc.**

**+2.9**

- Increase of licensing revenue

## Sales



**Total ¥250.0 billion (+44.1 from FY2016)**

**Sales price**

-1.5

**Volume**


+44.8

**Foreign exchange**

+0.8

- Expansion of production capacity for lithium-ion secondary battery separator
- New consolidation of Tanaka Chemical Corp.
- Sales expansion of engineering plastics and resorcinol

## Operating income



**Total ¥12.0 billion (+4.8 from FY2016)**

**Price variance**

-1.5

**Cost variance**


-1.5

**Volume variance etc.**

+7.8

- Increase in fixed cost due to expansion of production capacity for lithium-ion secondary battery separator
- Expansion of production capacity for lithium-ion secondary battery separator
- Sales expansion of engineering plastics and resorcinol

## Sales



## Total ¥385.0 billion (+26.6 from FY2016)

### Sales price

-28.5

- Decline in selling price of polarizing film
- Decline in selling price of touchscreen panels

### Volume


+48.3

- Increase in shipment of polarizing film
- Increase in shipment of touchscreen panels

### Foreign exchange

+6.8

## Operating income



## Total ¥21.0 billion (+10.7 from FY2016)

### Price variance

-27.5

- Decline in selling price of polarizing film
- Decline in selling price of touchscreen panels

### Cost variance

+14.5

- Rationalization of the use of raw materials
- Improvement of production yield


### Volume variance etc.

+23.7

- Increase in shipment of polarizing film
- Increase in shipment of touchscreen panels



## Sales



**Total ¥380.0 billion (+60.7 from FY2016)**

**Sales price**

**+2.0**

- Recovery of market price for feed additive methionine

**Volume**


**+54.4**

- Increase in shipment of crop protection chemical in overseas market

**Foreign exchange**

**+4.3**

## Operating income



**Total ¥60.0 billion (+13.8 from FY2016)**

**Price variance**

**+1.0**

- Recovery of market price for feed additive methionine

**Cost variance**

**-4.0**


- Increase in R&D cost

**Volume variance etc.**

**+16.8**

- Increase in shipment of crop protection chemical in overseas market

**Sales**



**Total ¥480.0 billion (+35.8 from FY2016 )**

**Sales price**

0

**Volume**


+31.8

- Increase in shipment of Latuda® in North America

**Foreign exchange**

+4.0

**Operating income**



**Total ¥57.0 billion (+1.9 from FY2016 )**

**Price variance**

0

**Cost variance**

-18.0

- Increase of sales expense related with new products

**Volume variance etc.**

+19.9

- Increase in shipment of Latuda® in North America

Unit; billions of yen

	FY2016	FY2017 (estimated)	Difference
Cash flows from operating activities	187.4	<b>190.0</b>	2.6
Cash flows from investing activities	<b>-199.7</b>	<b>-150.0</b>	49.7
Free cash flows	<b>-12.3</b>	<b>40.0</b>	52.3
Cash flows from financing activities	<b>-8.1</b>	<b>-40.0</b>	<b>-31.9</b>
Effect of exchange rate changes on cash and cash equivalents	<b>-1.9</b>	<b>0.0</b>	1.9
Net change in cash and cash equivalents	<b>-22.3</b>	<b>0.0</b>	22.3
Interest-bearing debt balance	875.3	<b>870.0</b>	<b>-5.3</b>

**(Reference: Segment Information)**

Unit; billions of yen

	FY2015				FY2016			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Petrochemicals & Plastics	198.5	163.6	156.3	138.7	137.0	128.7	148.4	158.0
Energy & Functional Materials	52.5	52.6	52.0	51.9	47.0	47.5	51.5	59.9
IT-related Chemicals	104.1	104.0	96.6	79.8	86.0	88.7	95.1	88.6
Health & Crop Sciences	82.0	75.2	71.1	130.7	64.0	61.8	66.1	127.4
Pharmaceuticals	106.2	108.8	113.5	107.0	111.7	102.6	115.5	114.5
Others & Adjustments	13.4	15.0	12.4	16.0	10.9	14.7	12.7	16.1
<b>Total</b>	<b>556.6</b>	<b>519.3</b>	<b>501.9</b>	<b>524.0</b>	<b>456.6</b>	<b>444.0</b>	<b>489.3</b>	<b>564.5</b>

Unit; billions of yen

	FY2016				FY2017 (estimated)	
	1Q	2Q	3Q	4Q	1st Half	2nd Half
Petrochemicals & Plastics	137.0	128.7	148.4	158.0	300.0	340.0
Energy & Functional Materials	47.0	47.5	51.5	59.9	120.0	130.0
IT-related Chemicals	86.0	88.7	95.1	88.6	190.0	195.0
Health & Crop Sciences	64.0	61.8	66.1	127.4	150.0	230.0
Pharmaceuticals	111.7	102.6	115.5	114.5	235.0	245.0
Others & Adjustments	10.9	14.7	12.7	16.1	25.0	30.0
<b>Total</b>	<b>456.6</b>	<b>444.0</b>	<b>489.3</b>	<b>564.5</b>	<b>1,020.0</b>	<b>1,170.0</b>

Unit; billions of yen

	FY2015				FY2016			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Petrochemicals & Plastics	6.9	6.4	12.4	3.0	1.8	4.9	10.9	9.1
Energy & Functional Materials	0.0	2.3	1.2	-0.7	0.7	1.5	3.0	2.1
IT-related Chemicals	7.3	8.8	4.8	-1.0	1.4	1.1	6.5	1.4
Health & Crop Sciences	16.1	10.9	13.8	36.6	9.1	3.8	3.7	29.6
Pharmaceuticals	5.8	13.5	15.7	7.7	15.3	12.6	18.2	9.0
Others & Adjustments	-3.0	-0.9	-2.6	-0.7	-3.0	-1.8	-3.2	-3.1
Total	33.2	41.1	45.3	44.9	25.3	21.9	39.0	48.1

Unit; billions of yen

	FY2016				FY2017 (estimated)	
	1Q	2Q	3Q	4Q	1st Half	2nd Half
Petrochemicals & Plastics	1.8	4.9	10.9	9.1	13.0	14.0
Energy & Functional Materials	0.7	1.5	3.0	2.1	5.0	7.0
IT-related Chemicals	1.4	1.1	6.5	1.4	11.0	10.0
Health & Crop Sciences	9.1	3.8	3.7	29.6	13.0	47.0
Pharmaceuticals	15.3	12.6	18.2	9.0	28.0	29.0
Others & Adjustments	-3.0	-1.8	-3.2	-3.1	-5.0	-7.0
<b>Total</b>	<b>25.3</b>	<b>21.9</b>	<b>39.0</b>	<b>48.1</b>	<b>65.0</b>	<b>100.0</b>



Unit; billions of yen

	FY2015	FY2016	FY2017 (estimated)
Capital expenditures	103.8	<b>130.1</b>	140.0
Depreciation and amortization	116.6	<b>110.3</b>	119.0
Research & development expenses	155.8	<b>157.6</b>	168.0
Number of employees (as of March 31)	31,094	<b>32,536</b>	33,100

Unit; billions of yen

	FY2015	FY2016	Difference
Petrochemicals & Plastics	20.7	<b>27.7</b>	7.0
Energy & Functional Materials	20.6	<b>19.1</b>	<b>-1.5</b>
IT-related Chemicals	26.7	<b>33.7</b>	6.9
Health & Crop Sciences	15.5	<b>23.9</b>	8.4
Pharmaceuticals	13.9	<b>14.9</b>	1.1
Others & Adjustments	6.3	<b>10.8</b>	4.5
Total	103.8	<b>130.1</b>	26.4

Unit: billions of yen

	FY2016	FY2017 (estimated)	Difference
Petrochemicals & Plastics	27.7	<b>26.5</b>	<b>-1.2</b>
Energy & Functional Materials	19.1	<b>30.0</b>	10.9
IT-related Chemicals	33.7	<b>28.0</b>	<b>-5.7</b>
Health & Crop Sciences	23.9	<b>32.0</b>	8.1
Pharmaceuticals	14.9	<b>14.5</b>	<b>-0.4</b>
Others & Adjustments	10.8	<b>9.0</b>	<b>-1.8</b>
<b>Total</b>	<b>130.1</b>	<b>140.0</b>	<b>9.9</b>

Unit; billions of yen

	FY2015	FY2016	Difference
Petrochemicals & Plastics	22.2	<b>20.1</b>	<b>-2.1</b>
Energy & Functional Materials	11.8	<b>11.3</b>	<b>-0.5</b>
IT-related Chemicals	35.0	<b>31.8</b>	<b>-3.2</b>
Health & Crop Sciences	16.3	<b>17.3</b>	1.0
Pharmaceuticals	22.2	<b>20.7</b>	<b>-1.5</b>
Others & Adjustments	9.2	<b>9.1</b>	<b>-0.1</b>
<b>Total</b>	<b>116.6</b>	<b>110.3</b>	<b>-6.3</b>

Unit; billions of yen

	FY2016	FY2017 (estimated)	Difference
Petrochemicals & Plastics	20.1	22.5	2.4
Energy & Functional Materials	11.3	14.5	3.2
IT-related Chemicals	31.8	34.5	2.7
Health & Crop Sciences	17.3	17.0	-0.3
Pharmaceuticals	20.7	22.5	1.8
Others & Adjustments	9.1	8.0	-1.1
<b>Total</b>	<b>110.3</b>	<b>119.0</b>	<b>8.7</b>

Unit; billions of yen


	FY2015	FY2016	Difference
Petrochemicals & Plastics	6.2	<b>6.0</b>	<b>-0.1</b>
Energy & Functional Materials	8.0	<b>9.1</b>	1.1
IT-related Chemicals	16.6	<b>16.0</b>	<b>-0.6</b>
Health & Crop Sciences	26.8	<b>27.8</b>	1.0
Pharmaceuticals	83.7	<b>83.1</b>	<b>-0.6</b>
Others & Adjustments	14.5	<b>15.5</b>	1.0
<b>Total</b>	<b>155.8</b>	<b>157.6</b>	<b>1.8</b>

Unit; billions of yen


	FY2016	FY2017 (estimated)	Difference
Petrochemicals & Plastics	6.0	7.0	1.0
Energy & Functional Materials	9.1	9.0	-0.1
IT-related Chemicals	16.0	16.5	0.5
Health & Crop Sciences	27.8	33.0	5.2
Pharmaceuticals	83.1	87.0	3.9
Others & Adjustments	15.5	15.5	-0.0
<b>Total</b>	<b>157.6</b>	<b>168.0</b>	<b>10.4</b>

Company	Net Sales		Profit Trends
	FY2015	FY2016	
The Polyolefin Company (Singapore) (millions of USD)	1,180	1,092	→ Maintaining due to better margins
Petrochemical Corporation of Singapore (millions of USD)	2,409	2,360	↗ Maintaining due to better margins
Rabigh Refining and Petrochemical Company (millions of SAR)	25,514	25,146	↗ Increased due to periodic plant maintenance in the previous fiscal year, inventory valuation gains from higher raw material prices and other factors
Dongwoo Fine-Chem (billions of KRW)	2,149	2,137	↘ Decreased due to lower selling price and other factors despite higher sales volume
Valent U.S.A. and Subsidiaries (millions of USD)	885	913	↘ Decreased due to difference of product mix





Overseas sales ratio **60.7%**



Overseas sales ratio **61.3%**


Sales

Profit

(¥ billion)




(¥ billion)




## Interest-bearing liabilities

## D/E ratio



## Dividends per share

## Payout ratio



(Notes) Payout ratio for FY2011 was 263.3%.  
Net income attributable to owners of the parents for FY2012 was -51.1 billions of yen.